| Project/Area Number |
14570722
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
SUMAZAKI Ryo University of Tsukuba, Institute of Clinical Medicine, Associate Professor, 臨床医学系, 助教授 (40163050)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ONODERA Masashi University of Tsukuba, Institute of Clinical Medicine, Assistant Professor, 臨床医学系, 講師 (10334062)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2002: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | Epstein-Barr Virus / X-linked lymphoproliferative disease / SAP(SLAM-associated protein) / SH2D1A / primary immunodeficiency / T lymphocytes / early diagnosis / vasculitis / Epstein-Barr ウイルス / SAP (SLAM-associated protein) / リンパ球 / Epstein-Barrウィルス / flow cytometry (フローサイトメトリー) / T細胞活性化 |
|---|
| Research Abstract |
X-linked lymphoproliferative disease (XLP, MIM 308240) is a genetic disorder characterized by immunodeficiency to Epstein-Barr virus (EBV) infection. Recently, an SH2-domain-encoding gene, SH2DIA/SAP was identified as the causative gene of XLP and the genetic diagnosis applied to the family members of XLP patients provides the tool for finding pre-symptomatic XLP patients. However, the easy method for definitive diagnosis and the therapeutic strategy for these pre-symptomatic patients are largely unknown. Especially, because of the poor prognosis in symptomatic XLP patients, early diagnosis and treatment for the presymptomatic patients are clinically of great importance. The research was performed to solve these problems based on the molecular pathology of XLP patients.
<Results>
1. We have establish the new and easy method for the XLP diagnosis, using the specific monoclonal antibody against recombinant SAP protein and flow-cytometric detection of SAP protein in the lymphocytes obtained from patient's blood.
2. We have found that SAP protein dosage is regulated by the lymphocyte activation and that SAP-deficient lymphocytes cannot activate killer function to target cells.
3. Two XLP patients, who had survived the EBV infection and kept good health for more than 5 years after EBV infection, suddenly suffered from severe lymphocytic vasculitis.
<Discussion and Conclusions>
Our study indicates that easy flow-cytometric analysis provides definitive XLP diagnosis without time-consuming and expensive mutational analysis. Inducible SAP expression is needed for the gene therapy for the XLP patients. Apparently healthy persons with SAP mutations are very dangerous to severe lymphocytic vasculitis and thus, almost all pre-symptomatic XLP patients may need blood stem cell transplantation.
|
